SHAREHOLDER ALERT: Weiss Law Reminds APEN, HZN, CBIO, and AJRD Shareholders About Its Ongoing Investigations

SHAREHOLDER ALERT: Weiss Law Reminds APEN, HZN, CBIO, and AJRD Shareholders About Its Ongoing Investigations

PR Newswire

NEW YORK, Jan. 18, 2023 /PRNewswire/ --

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7th Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
[email protected]

Apollo Endosurgery, Inc. (NASDAQ: APEN)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Apollo Endosurgery, Inc. (NASDAQ: APEN), in connection with the proposed acquisition of APEN by Boston Scientific Corporation.  Under the terms of the merger agreement, APEN shareholders will receive $10.00 in cash for each share of APEN common stock owned.  If you own APEN shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/apen

Horizon Global Corporation (NYSE: HZN)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Horizon Global Corporation (NYSE: HZN) in connection with the proposed acquisition of HZN by First Brands Group, LLC, via tender offer.  Under the tender offer, HZN shareholders will receive $1.75 in cash for each share of HZN common stock owned.  If you own HZN shares and wish to discuss this investigation or your rights, please call at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/hzn

Catalyst Biosciences, Inc. (NASDAQ: CBIO)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Catalyst Biosciences, Inc. (NASDAQ: CBIO), in connection with the proposed purchase of GNI Group Ltd.'s ("GNI") proprietary new chemical entity F351 ("F351").  This purchase will transfer the global rights to F351 (excluding Mainland China) to CBIO in consideration of 6,266,521 shares of common stock and 12,340 shares of a new series of preferred stock ("Series X") with economic rights equivalent to CBIO common stock to be paid for GNI's 65.18% interest of Beijing Continent ("Continent"), a China based commercial-stage pharmaceutical company marketing pirfenidone and having the rights to F351 in China.  If you own CBIO shares and wish to discuss this investigation or your rights, please call at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/cbio  

Aerojet Rocketdyne Holdings, Inc. (NYSE: AJRD)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Aerojet Rocketdyne Holdings, Inc. (NYSE: AJRD), in connection with the proposed acquisition of AJRD by L3Harris Technologies, Inc. Under the terms of the merger agreement, AJRD shareholders will receive $58.00 in cash for each share of AJRD common stock owned.  If you own AJRD shares and wish to discuss this investigation or your rights, please call at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/ajrd  

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-weiss-law-reminds-apen-hzn-cbio-and-ajrd-shareholders-about-its-ongoing-investigations-301725064.html

SOURCE Weiss Law

Copyright CNW Group 2023